Medmonitor

An up-to-date timeline of U.S. Food and Drug Administration (FDA) approvals that could potentially impact workers' compensation. These include new drug and indication approvals, new dosages or formulations of existing products, and generics introduced to the market. Click through the interactive timeline below, or select the comprehensive list view.
← Back to Medmonitor

Medication Type: Opioid-Induced Constipation

Relistor® (methylnaltrexone bromide) injection

Approval Date: Aug 2024

Note: First-Time Generic

Indicated for the treatment of opioid-induced constipation

Amitiza (lubisprostone) capsules

Approval Date: Nov 2021

Note: First-Time Generic

Indicated for the treatment of opioid-induced constipation

Medication Name

Approval Date

Category

Description

Relistor® (methylnaltrexone bromide) injection

Aug 2024

Indicated for the treatment of opioid-induced constipation

Note: First-Time Generic

Amitiza (lubisprostone) capsules

Nov 2021

Indicated for the treatment of opioid-induced constipation

Note: First-Time Generic
lockenvelopephone-handsetmagnifiermenucross-circle